Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-103 + CST-107 in Neurodegenerative Disorders
NCT04739423Phase 2Completed
- Sponsor
- CuraSen Therapeutics
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of clenbuterol in Parkinson's disease (PD), Mild Cognitive Impairment (MCI), dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), sponsored by CuraSen Therapeutics. Started Jun 2021; status: completed.
02
Drugs
clenbuterol
03
Conditions
Parkinson's disease (PD)Mild Cognitive Impairment (MCI)dementia with Lewy bodies (DLB)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT04739423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739423.